linkedin

Press Releases

News Brief

Samsung Biologics wins Asia-Pacific Vaccine Excellence Award 2021(AVEA 2021)

16_9.png
 

Samsung Biologics announced the winning of an award for the Best Vaccine CMO of the Year from Asia-Pacific Vaccine Excellence Award 2021(AVEA 2021), hosted by IMAPAC (Impactful Connections and Intelligence), a networking foundation that provides one-stop shop of market intelligence and business connections for biopharmaceutical professionals and businesses. 

 

The Asia-Pacific Vaccine Excellence Awards aims to recognize Asia's vaccine manufacturers who have engaged in substantial efforts to innovate, optimize processes and uphold a high level of efficacy, quality, and safety in vaccine development and manufacturing. Samsung Biologics is currently in agreement with Moderna to provide large scale, commercial fill-finish manufacturing for mRNA-1273, Moderna’s COVID-19 vaccine which was announced in May this year. 

 

"It's an honor to receive this award and be recognized as a team for our efforts and capabilities to manufacture vaccines in a short time frame," said David King, Director of Drug Product Operations at Samsung Biologics. "Samsung Biologics has grown tremendously within the past decade and I would like to take this opportunity to thank all the teams and also the clients for the generous support they have shown us to successfully manage the manufacturing processes throughout." 

16_9.png
 

Samsung Biologics announced the winning of an award for the Best Vaccine CMO of the Year from Asia-Pacific Vaccine Excellence Award 2021(AVEA 2021), hosted by IMAPAC (Impactful Connections and Intelligence), a networking foundation that provides one-stop shop of market intelligence and business connections for biopharmaceutical professionals and businesses. 

 

The Asia-Pacific Vaccine Excellence Awards aims to recognize Asia's vaccine manufacturers who have engaged in substantial efforts to innovate, optimize processes and uphold a high level of efficacy, quality, and safety in vaccine development and manufacturing. Samsung Biologics is currently in agreement with Moderna to provide large scale, commercial fill-finish manufacturing for mRNA-1273, Moderna’s COVID-19 vaccine which was announced in May this year. 

 

"It's an honor to receive this award and be recognized as a team for our efforts and capabilities to manufacture vaccines in a short time frame," said David King, Director of Drug Product Operations at Samsung Biologics. "Samsung Biologics has grown tremendously within the past decade and I would like to take this opportunity to thank all the teams and also the clients for the generous support they have shown us to successfully manage the manufacturing processes throughout."

SITE MAP

close
Close

Thank you for Subscribing to Our Newsletter

아래 다운로드 버튼을 클릭하시면 바로 다운로드 하실 수 있습니다.

Close

Subscribe to Our Newsletter

파일 다운로드를 위해 뉴스레터 구독용 이메일 주소를 입력해주세요.
* 구독자라면 구독중인 이메일 주소를 입력해주세요.

뉴스레터 구독 서비스 유무 확인
Close

Subscribe to Our Newsletter

뉴스레터 구독 서비스를 등록하시면 당사 뉴스룸에서 제공되는
삼성바이오로직스의 최신 소식과 관심 분야별 유용한 정보를 받아 보실 수 있습니다.

Subscribe to Our Newsletter
    • - 개인정보 수집 목적 : 이메일 발신서비스 제공
    • - 개인정보 수집 항목 : 이메일 주소, 회사명, 이름, 직급, 국가
    • - 이용 및 보관 기간 : 이메일 발신서비스 해지 시까지

    개인정보 수집에 동의하지 않을 시, 뉴스레터 서비스를 이용할 수 없습니다.

    삼성바이오로직스 개인정보 보호정책에 따라 개인정보는 안전하게 관리됩니다.

close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION

Copyright Samsung Biologics. All rights reserved